Merck & Co., Inc. (MRK) Shares Sold by Alpha Windward LLC

Share on StockTwits

Alpha Windward LLC reduced its stake in Merck & Co., Inc. (NYSE:MRK) by 9.1% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 5,007 shares of the company’s stock after selling 501 shares during the period. Alpha Windward LLC’s holdings in Merck & Co., Inc. were worth $383,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of MRK. Bank of New York Mellon Corp raised its holdings in Merck & Co., Inc. by 184,252.6% in the 3rd quarter. Bank of New York Mellon Corp now owns 38,985,039 shares of the company’s stock valued at $2,765,600,000 after buying an additional 38,963,892 shares during the period. Capital International Investors grew its position in Merck & Co., Inc. by 178.2% in the 3rd quarter. Capital International Investors now owns 32,984,606 shares of the company’s stock valued at $2,339,928,000 after acquiring an additional 21,127,887 shares in the last quarter. Janus Henderson Group PLC grew its position in Merck & Co., Inc. by 64.3% in the 3rd quarter. Janus Henderson Group PLC now owns 20,519,549 shares of the company’s stock valued at $1,455,653,000 after acquiring an additional 8,032,634 shares in the last quarter. Matthew Goff Investment Advisor LLC grew its position in Merck & Co., Inc. by 5,970.0% in the 3rd quarter. Matthew Goff Investment Advisor LLC now owns 5,369,519 shares of the company’s stock valued at $88,460,000 after acquiring an additional 5,281,059 shares in the last quarter. Finally, Senator Investment Group LP acquired a new position in Merck & Co., Inc. in the 2nd quarter valued at about $285,594,000. Hedge funds and other institutional investors own 74.29% of the company’s stock.

In other news, Director Leslie A. Brun sold 3,052 shares of the business’s stock in a transaction dated Friday, February 8th. The stock was sold at an average price of $77.22, for a total transaction of $235,675.44. Following the completion of the transaction, the director now directly owns 5,000 shares of the company’s stock, valued at $386,100. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Chairman Kenneth C. Frazier sold 231,566 shares of the business’s stock in a transaction dated Tuesday, February 5th. The stock was sold at an average price of $78.08, for a total value of $18,080,673.28. Following the transaction, the chairman now directly owns 923,516 shares of the company’s stock, valued at $72,108,129.28. The disclosure for this sale can be found here. Over the last three months, insiders have sold 244,618 shares of company stock valued at $19,075,949. Corporate insiders own 0.32% of the company’s stock.

Several equities analysts have weighed in on the company. Zacks Investment Research raised Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $83.00 target price for the company in a research report on Friday, January 4th. BMO Capital Markets lifted their target price on Merck & Co., Inc. from $70.00 to $82.00 and gave the company an “outperform” rating in a research report on Monday, October 22nd. ValuEngine raised Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research report on Thursday, October 18th. Credit Suisse Group set a $86.00 target price on Merck & Co., Inc. and gave the company a “buy” rating in a research report on Thursday, December 13th. Finally, Wolfe Research assumed coverage on Merck & Co., Inc. in a research report on Tuesday, October 23rd. They issued an “outperform” rating for the company. Six equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $73.15.

Shares of Merck & Co., Inc. stock opened at $79.02 on Thursday. Merck & Co., Inc. has a one year low of $52.83 and a one year high of $80.19. The stock has a market cap of $209.82 billion, a PE ratio of 18.21, a P/E/G ratio of 2.05 and a beta of 0.62. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.44 and a quick ratio of 1.15.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings data on Friday, February 1st. The company reported $1.04 EPS for the quarter, topping the Zacks’ consensus estimate of $1.03 by $0.01. Merck & Co., Inc. had a return on equity of 35.10% and a net margin of 14.71%. The business had revenue of $11 billion during the quarter, compared to the consensus estimate of $10.93 billion. During the same period in the previous year, the company posted $0.98 earnings per share. The business’s revenue for the quarter was up 5.4% on a year-over-year basis. On average, sell-side analysts predict that Merck & Co., Inc. will post 4.65 earnings per share for the current year.

Merck & Co., Inc. declared that its Board of Directors has approved a share buyback program on Thursday, October 25th that authorizes the company to buyback $10.00 billion in shares. This buyback authorization authorizes the company to purchase up to 5.1% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s board believes its stock is undervalued.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 5th. Stockholders of record on Friday, March 15th will be given a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 2.78%. The ex-dividend date of this dividend is Thursday, March 14th. Merck & Co., Inc.’s dividend payout ratio is presently 50.69%.

TRADEMARK VIOLATION NOTICE: “Merck & Co., Inc. (MRK) Shares Sold by Alpha Windward LLC” was originally published by Macon Daily and is owned by of Macon Daily. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of international trademark & copyright law. The correct version of this news story can be read at https://macondaily.com/2019/02/14/merck-co-inc-mrk-shares-sold-by-alpha-windward-llc.html.

Merck & Co., Inc. Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

Featured Article: Asset Allocation, Balancing Your Investments

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply